Of note, we report here for the first time that EGFRvIII (a mutant form of EGFR with deletion of exons 2–7 of the gene) may play a role in a small subset of malignant phyllodes tumors, adding this cancer to the growing list of malignancies with this type of mutation [40], and potentially eligible for tumor directed immunotherapy. This evidence concerns the gene EGFR and neoplasm.